Cargando…
PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas
Ras proteins, most notably KRas, are prevalent oncogenes in human cancer. Plasma membrane localization and thereby signaling of KRas is regulated by the prenyl‐binding protein PDEδ. Recently, we have reported the specific anti‐proliferative effects of PDEδ inhibition in KRas‐dependent human pancreat...
Autores principales: | Klein, Christian H., Truxius, Dina C., Vogel, Holger A., Harizanova, Jana, Murarka, Sandip, Martín‐Gago, Pablo, Bastiaens, Philippe I.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519276/ https://www.ncbi.nlm.nih.gov/pubmed/30194764 http://dx.doi.org/10.1002/ijc.31859 |
Ejemplares similares
-
Identification of pyrazolopyridazinones as PDEδ inhibitors
por: Papke, Björn, et al.
Publicado: (2016) -
Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019) -
Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
por: Lee, Jungeun, et al.
Publicado: (2022) -
EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells
por: Chen, Yue-hong, et al.
Publicado: (2019) -
Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis
por: Le Roux, Özgün, et al.
Publicado: (2022)